Paris and Boston (ots/PRNewswire) – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive global collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The agreement includes an option under which Ipsen would acquire an exclusive license to the worldwide rights to develop successful DC candidates. After the successful DC nomination, Ipsen will be responsible for all activities. Skyhawk’s unique platform accelerates the development of small molecules that target RNA in diverse therapeutic areas, including rare neurological diseases.2
- Ipsen enters into an option agreement to obtain exclusive global rights to two candidates being pursued as part of the collaboration
- Following validation of the development candidate, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscientific expertise in movement disorders.
- This promising platform technology developed by Skyhawk enables the exploration of previously untreatable small molecule RNA targets, expanding the landscape of disease targets1
“We are pleased to collaborate with Skyhawk’s expert teams to explore the potential for altering RNA expression in rare and debilitating neurological diseases,” said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen. “Our Our focus and expertise in the area of movement disorders and across our portfolio is to bring the best and most premium treatments to those with the greatest unmet need, which will now be further advanced through this novel platform at the forefront of research.”
“Ipsen is an exceptional company with a deep passion for patients, and we are excited to work with them to expand their pipeline of innovative therapies,” said Sergey Paushkin, Chief Scientific Officer at Skyhawk. “Our strategic partnership underlines our shared goal of developing innovative medicines for people with rare neurological diseases for which there are no approved therapeutics.”
Under the agreement, Skyhawk is eligible to receive up to $1.8 billion in development, regulatory and commercial milestones, including an upfront payment, option and research collaboration, as well as possible tiered royalties.
Information about Ipsen
We are a global biopharmaceutical company focused on bringing innovative medicines to patients in three therapeutic areas: oncology, rare diseases and neuroscience.
Our pipeline is driven by external innovation and supported by nearly 100 years of development experience and global centers in the US, France and the UK. Our teams in more than 40 countries and our partnerships around the world enable us to provide medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the USA through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecules that modulate RNA. Skyhawk’s discovery expertise is based on its proprietary drug discovery platform, which develops small molecule drug candidates targeting RNA splicing targets in a variety of therapeutic areas, including neurodegenerative diseases, autoimmune diseases and oncology. For more information, see www.skyhawktx.com.
Ipsen Contact
E-Mail: corporate.communications@ipsen.com
Amy Wolf | +41 7 95 76 07 23
Jess Smith | + 44 7557 267 634
Skyhawk-Kontakte Maura McMarthy E-Mail: maura@skyhawktx.com
Ipsen disclaimers and/or forward-looking statements
The forward-looking statements, objectives and objectives contained herein are based on Ipsen management’s strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated. All of the foregoing risks could impact Ipsen’s future ability to achieve its financial objectives, which were established assuming reasonable macroeconomic conditions based on information available today. The use of the words “believes,” “anticipates,” and “expects” and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations with respect to future events, including regulatory filings and decisions. In addition, those described in this document Targets are prepared without taking into account external growth assumptions and possible future acquisitions that could change these parameters. These targets are based on data and assumptions that Ipsen believes are appropriate. These targets depend on conditions or facts that are likely to occur in the future not solely based on historical data. Actual results may differ significantly from these targets due to certain risks and uncertainties, particularly the fact that a promising drug in early development or clinical testing may never be brought to market, particularly for regulatory or competitive reasons market or achieve its commercial goals. Ipsen faces or may face generic competition, which could result in a loss of market share. In addition, the research and development process involves several phases, each of which poses a significant risk that Ipsen will not achieve its objectives and will be forced to abandon its efforts to produce a drug in which it has invested significant sums. Therefore, Ipsen cannot be sure that the positive results obtained in the preclinical trials will later be confirmed in the clinical trials or that the results of the clinical trials will be sufficient to demonstrate the safety and effectiveness of the drug in question. There can be no guarantee that a drug will receive the necessary approvals or that it will prove commercially successful. Should the underlying assumptions prove incorrect or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, including interest rate and exchange rate fluctuations, the impact of pharmaceutical industry regulation and health care legislation, global health care cost containment trends, technological advances, new medications and patents from competitors; challenges in developing new drugs, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; production difficulties or delays; the financial instability of international economies and country risks; dependence on the effectiveness of Ipsen’s patents and other protection mechanisms for innovative medicines; and the risk of litigation, including patent litigation, and/or regulatory action. Ipsen also depends on third parties to develop and commercialize some of its drugs, which could potentially generate substantial royalties; these partners could behave in a manner that could harm Ipsen’s operations and financial results. Ipsen cannot be certain that its partners will fulfill their obligations. The Company may not be able to derive any benefit from these arrangements. A failure of one of Ipsen’s partners could result in lower revenue than expected. Such situations could have an adverse effect on Ipsen’s business, financial condition or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, objectives or estimates contained in this press release to reflect any changed events, conditions, assumptions or circumstances on which such statements are based, except as follows: is required by applicable law. Ipsen’s operations are subject to the risk factors described in the registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties presented are not exhaustive and the reader is encouraged to review Ipsen’s most recent unified registration document, which can be found at ipsen.com is available.
credentials
1 Drugging RNA, Nature Article. https://www.nature.com/articles/s41587-023-01790-z
2 Skyhawk Therapeutics. https://www.skyhawktx.com/platform
Logo – https:// mma.prnewswire.com/media/710814/Skyhawk_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/ipsen-und-skyhawk-therapeutics-geben-zusammenarbeit-bei-der-erforschung-seltener-neurologischer-erkrankungen-durch-rna-targeting-bekannt-302125429.html